Content

Treatment of an Acute MH Crisis


If you suspect an MH crisis in a patient under a triggering anesthesia, follow these steps to manage the MH crisis. Click on each step to view detailed information. Caution: This protocol may not apply to every patient and may require modification depending on specific needs of each patient.


  1. Look for signs and symptoms
  2. Call for help and discontinue trigger
  3. Administer dantrolene
  4. Administer bicarbonate
  5. Administer anti-arrhythmic agents if needed - but not calcium channel blockers
  6. Monitor other variables
  7. Treat hyperkalemia if needed
  8. Monitor fluid shifts and and urine output

1. Look for signs and symptoms

Look for signs and symptoms of an MH reaction:

  • hypercarbia
  • tachypnoea
  • tachycardia
  • cardiac arrhythmias
  • rigidity
  • cyanosis/mottling
  • unstable or increasing blood pressure
  • fever
  • respiratory and metabolic acidosis
  • myoglobinuria

Back to Top of Page


2. Call for help and discontinue trigger

Call for help! Immediately discontinue all volatile inhalation anesthetics and succinylcholine. Hyperventilate with 100% oxygen at high gas flows, at least 10 L/min. A clean circuit should be used if possible, without delaying other important treatment.

Back to Top of Page


3. Administer dantrolene

Immediately begin dantrolene sodium 2.5 mg/kg. Rapidly administer the initial bolus intravenously with supplemental increments up to 10mg/kg. A central venous line is preferred in order to avoid peripheral venous thrombosis. Each vial of dantrolene contains 20 mg dantrolene and 3 g mannitol. One vial should be mixed with 60 mL of sterile water for injection (USP). Continue to administer dantrolene until signs of MH (e.g. hypercarbia, rigidity, tachycardia and fever) are controlled. Occasionally more than 10 mg/kg dantrolene total dose may be needed, but clinical reassessment is suggested.

Back to Top of Page


4. Administer bicarbonate

Administer bicarbonate to correct metabolic acidosis as guided by blood gas analysis. In the absence of blood gas analysis, 1-2 mEq/kg should be administered.

Back to Top of Page


5. Administer anti-arrhythmic agents if needed

Arrhythmias will usually respond to treatment of acidosis and hyperkalemia. If they persist or are life-theatening, standard anti-arrhythmic agents may be used. If dantrolene has been administered, do not use calcium channel blockers as they can interact to produce fatal hyperkalemia and cardiovascular collapse.

Back to Top of Page


6. Monitor other variables

Determine, monitor and treat:

  • end tidal CO2
  • arterial, central or femoral venous blood gases
  • serum potassium
  • calcium
  • CK
  • serum and urine myoglobin
  • blood cultures
  • thyroid function studies
  • clotting studies
  • urine output

Respiratory and renal failure and disseminated intravascular coagulation may need appropriate supportive measures.

Back to Top of Page


7. Treat hyperkalemia if needed

Hyperkalemia is common and should be treated with hyperventilation, bicarbonate and intravenous glucose and insulin (e.g. 10 units regular insulin in 50 mL 50% glucose titrated to potassium level). Life-threatening arrhythmias from hyperkalemia should be treated with IV calcium (10-30 mg/kg of IV calcium chloride).

Back to Top of Page


8. Monitor fluid shifts and and urine output

Ensure urine output of greater than 2 mL/kg/hr by hydration and/or administration of mannitol or furosemide. Remember that each vial of dantrolene contains 3 grams of mannitol. Consider central venous or pulmonary arterial monitoring because fluid shifts may result in hemodynamic instability.


Back to Top of Page